Die FDA hat die Anwendung der allogenen regulatorischen T-Zell-Immuntherapie, HSPC und T-Zell-vldq, zur Behandlung von hämatologischen Malignomen bei Erwachsenen mittels Transplantation von hämatopoetischen Stammzellen von passenden Spendern zugelassen.
Die .gov-Endung kennzeichnet eine offizielle Website.
Vollstaendiger Artikelinhalt
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Haeufig gestellte Fragen
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
